

Inventor(s): Nabil Hanna et al.

Appln. No.: 09

435,992

Series Code ↑

Serial No. ↑

Filed: November 8, 1999

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Date: April 16, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input checked="" type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously		For B & C See <u>Required</u> <u>Separate Paper</u> (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm	
2. Total Effective Claims				41	**minus	56	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims				3	***minus	3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)						add	+ \$270/\$135 =	+ \$0	104/204	
5. Original due Date: April 15, 2001				<input type="checkbox"/> NONE						
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo)		\$110/\$55 =	+ \$0		115/215	
				(2 mos)		\$390/\$195 =			116/216	
				(3 mos)		\$890/\$445 =			117/217	
				(Usable only for ≤ 2mo.OA --- 4 mos)		\$1390/\$695=			118/218	
				(Usable only for 30 day/1mo.OA --- 5 mos)		\$1890/\$945=			128/228	
7. Enter any previous extension fee paid since above original due date and subtract						- \$0				
8. Extension Fee Attached						+ \$0				
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ \$110/\$55	+ \$0	148/248		
10. If IDS attached requires Official Fee under Rule 97 (c),						+ \$180	+ \$0	126		
or if Rule 97(d) Request						+ \$180	+ \$0	126		
11. After-Final Request Fee per rules 129(a) and 17(r)						+ \$710/355	+ \$0	146/246		
12. No. of additional inventions for examination per Rule 129(b).....						x \$710/355 ea	+ \$0	149/249		
13. Request for Continued Examination (RCE)						+ \$710/355	+ \$0	1179/1279		
14. Petition fee for						+ \$0				
15. TOTAL FEE ENCLOSED =						\$0				

15.

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.


This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Sig:



Reg. No. 35,030

Fax: (202) 822-0944

Tel: (202) 861-3623

1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty/Sec: RLT/kmh

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

Inventor(s): Nabil Hanna et al.

Appln. No.: 09

435,992

Series Code ↑

Serial No. ↑

Filed: November 8, 1999

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Unit

Examiner:

Atty. Dkt.

P


P. Gambel

0275478

M#

Client Ref

Appln. Title:

Treatment of B Cell Malignancies Using
Anti-CD40L Antibodies in Combination
with Anti-CD20 Antibodies and/or
Chemotherapeutics and Radiotherapy

Sir:

REPLY/AMENDMENT/LETTER

Date: April 16, 2001

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☒ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required
Separate Paper**
(Pat-256)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	41	**minus 56	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	3	***minus 3	0	x \$80/\$40 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				+ \$270/\$135 =	+ \$0	104/204
5. Original due Date: April 15, 2001	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) \$110/\$55 = (2 mos) \$390/\$195 = (3 mos) \$890/\$445 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1390/\$695= (Usable only for 30 day/1mo.OA --- 5 mos) \$1890/\$945=			+ \$0		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0		
8.				Extension Fee Attached	+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),				+ \$180	+ \$0	126
or if Rule 97(d) Request				+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$710/355	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)				x \$710/355 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)				+ \$710/355	+ \$0	1179/1279
14. Petition fee for					+ \$0	
15.				TOTAL FEE ENCLOSED =	\$0	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 | 0275478

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1100 New York Avenue, NW

Ninth Floor

Washington, DC 20005-3918

Tel: (202) 861-3000

Atty/Sec: RLT/kmh

Sig:

Fax:

(202) 822-0944

Tel:

(202) 861-3623

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil Hanna et al.

Application Serial No. 09/435,992

Filed: November 8, 1999

Group Art Unit: 1644

Examiner: P. Gambel

TECH CENTER 1600/2908



Title: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION
WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY

* * * * *

ELECTION

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Official Action [Restriction Requirement] dated March 15, 2001,
Applicants elect without traverse Group I, Claims 1-41.

As the elected species Applicants further elect Group B directed to use of an anti-CD40L specific antibody and an anti-CD20 specific antibody. It is assumed that this requirement is only for purposes of examination and that the Examiner will extend the search to other species upon a determination that the elected combination is patentable. At the very least, the search should be extended to use of anti-CD40L antibody alone for treatment of lymphoma as this certainly is overlapping with the elected species.

If the Examiner has any questions in connection with this election, he should contact the undersigned so that prosecution may be expedited.

In view of the foregoing, the claims are now believed to be in form for allowance, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

Election

U.S. Serial No. 09/435,992


Atty Reference: 037003-0275478

Page 2

All objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Respectfully submitted,

Pillsbury Winthrop LLP

By: 

Robin L. Teskin

Registration No. 35,030

1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
(202) 861-3623
(202) 822-0944 Facsimile

Date: April 16, 2001